Here are Thursday's biggest analyst calls of the day: Nvidia, SpaceX, Imax, Meta, CoreWeave, Tesla & more

Wall Street's Thursday call sheet skewed constructive, led by JPMorgan upgrading CoreWeave to overweight on stronger compute pricing and Meta remaining overweight with its price target lifted to $920 from $820. Other notable bullish actions included Morgan Stanley reiterating Nvidia as overweight, HSBC upgrading Dollar General to buy with a $160 target, and JPMorgan upgrading Welltower and Macerich to overweight. The principal negative call was Citi's downgrade of Dropbox to sell with a $29 target, citing valuation that prices in too much early success from its AI-storage pivot.

Analysis

The highest-quality read-through is the AI infrastructure complex, but the relative opportunity is more compelling than a blanket long. CRWV’s willingness to monetize scarce capacity through shorter-duration, premium contracts can lift near-term revenue yield and EBITDA, yet it also raises renewal/asset-utilization risk when GPU supply normalizes. Long NVDA versus CRWV is the cleaner 6-18 month expression: NVDA retains the hardware/software toll-collector economics while CRWV carries financing, customer-concentration and residual-value risk that premium spot pricing can temporarily conceal.

PWR’s advantage is not simply backlog growth; scarce skilled labor and execution capacity create an oligopolistic margin structure that is difficult for EPC peers to replicate quickly. That supports a 1-3 quarter upside path through conversion of booked work into higher-margin revenue, with second-order beneficiaries in grid equipment such as ETN, GEV and HUBB. The key falsifier is a material decline in utility/interconnection capital plans or evidence that labor and subcontractor costs are rising faster than bid repricing; absent that, PWR’s FCF-funded acquisition model can compound its capacity advantage.

Several upgrades appear more valuation-sensitive than earnings-revision-driven. WELL and MAC need rates to remain contained for multiple expansion, making them vulnerable to a 25-50 bp upward move in long-end Treasury yields even if operating results hold. DBX is the more actionable contrarian short: an AI-infrastructure narrative requires evidence of accelerating paid-seat growth, net revenue retention and gross-margin durability; without those, the market is likely capitalizing an option value that may not convert to cash flow. Biotech calls (ARCT, JAZZ) should remain watch items pending trial timing, endpoint quality and funding/runway review rather than analyst-rating momentum.

Key Decisions for Investors

• Initiate a 6-12 month pair: long NVDA / short CRWV in equal beta-weighted dollars. Target 15-20% relative outperformance as AI demand stays firm but compute-hosting contract-duration and capital-intensity risk reprice; stop if CRWV demonstrates sustained backlog growth with improving contract duration and net leverage.
• Accumulate PWR on market weakness for a 9-18 month hold; add ETN or GEV as a diversified grid-spending basket rather than chasing a single utility-capex winner. Underwrite mid-teens upside, with thesis invalidated by weaker utility capex guidance or gross-margin compression over two consecutive reports.
• Establish a 3-6 month DBX short, preferably through put spreads to cap takeover/AI-narrative squeeze risk. The catalyst is the next earnings report failing to show measurable improvement in revenue growth and retention; cover if management delivers durable reacceleration alongside stable or expanding gross margin.
• Avoid treating WELL and MAC upgrades as standalone catalysts; use a 10-year Treasury yield breakout as the entry filter. If yields remain range-bound or decline, favor WELL over MAC for a 6-12 month long due to more visible operating growth; if yields rise materially, reduce both before expecting cap-rate compression.
• Keep ARCT and JAZZ on an event-driven watchlist rather than initiating on coverage changes. Require independently verifiable clinical catalyst dates, probability-adjusted peak-sales assumptions and balance-sheet runway before sizing.